Boulder, CO, United States
Boulder, CO, United States
Time filter
Source Type

SHANGHAI, May 11, 2017 /PRNewswire/ -- China Rapid Finance Limited ("China Rapid Finance") (NYSE:XRF) today announced that the underwriters of its previously announced initial public offering have exercised in full the option to purchase an additional 1,500,000 American depositary shares ("ADSs") from China Rapid Finance to cover over-allotments. Each ADS represents one Class A ordinary share of China Rapid Finance and was sold at the initial public offering price of US$6.00 per ADS. Including the underwriters' full exercise of the over-allotment option, China Rapid Finance's offering size is a total of approximately US$69.0 million in the initial public offering. Morgan Stanley & Co. International plc, Credit Suisse Securities (USA) LLC and Jefferies LLC acted as joint bookrunners for the offering. A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on April 27, 2017. This offering is being made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus relating to the offering may be obtained, when available, by contacting the prospectus department at Morgan Stanley & Co. International plc at Room 214, 2nd Floor, 180 Varick Street, New York, NY, 10014, by telephone at 1-917-606-8487 or by emailing; Credit Suisse Securities (USA) LLC at One Madison Avenue, New York, NY 10010, United States, attention: Prospectus Department, by telephone at 1-800-221-1037 or by emailing; or Jefferies LLC at 520 Madison Ave., 2nd Floor, New York, NY 10022, by telephone at 1-877-547-6340 or by emailing This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. China Rapid Finance operates one of China's largest consumer lending marketplaces in terms of total number of loans, having facilitated approximately 15 million loans to approximately 2 million borrowers at significantly lower borrowing costs than many of its competitors. To view the original version on PR Newswire, visit:

Anderson K.M.,Room 214
Maternal and child health journal | Year: 2011

To identify gender differences in correlates of anticipation and initiation of sexual activity in the baseline survey of 562 African-American 5th grade students prior to initiation of a school-based pregnancy prevention intervention curriculum. Students from 16 elementary schools were administered the baseline questionnaire during classroom periods. Using these data, binary and ordered logistic regression models were used to analyze the factors affecting virginity and anticipation of sexual activity separately by gender, and tests of interaction between each factor and gender were conducted on the combined sample. More boys than girls had already had sex (18% vs. 5%) and anticipated having sexual intercourse in the next 12 months (56% vs. 22%). Boys and girls also differed in the factors that affected these outcomes. The perception that their neighborhood was safe reduced the odds that boys anticipated sexual activity but was not associated with this outcome among girls. Pubertal knowledge increased the odds of anticipation, but only among boys. Attitudes favoring abstinence decreased anticipation of sex among both genders, but slightly more among girls than boys. Having more frequent parent-child communication about sex was associated with increased anticipation among girls but decreased anticipation among boys. Curriculum based approaches to adolescent pregnancy prevention are appropriate for 5th grade elementary students who may already be anticipating sexual activity in communities with disproportionate rates of teen pregnancy. The design of the interventions should consider the differences in motivating factors by gender.

Abouzeid A.H.,Northeastern University | Patel N.R.,Northeastern University | Sarisozen C.,Northeastern University | Torchilin V.P.,Room 214
Pharmaceutical Research | Year: 2014

Purpose: The ability to successfully treat advanced forms of cancer remains a challenge due to chemotherapy resistance. Numerous studies indicate that NF-κB, a protein complex that controls the expression of numerous genes, as being a key factor in producing chemo-resistant tumors. In this study, the therapeutic potential of transferrin (TF)-targeted mixed micelles, made of PEG-PE and vitamin E co-loaded with curcumin (CUR), a potent NF-κB inhibitor, and paclitaxel (PCL), was examined. Methods: The cytotoxicity of non-targeted and TF-targeted CUR and PCL micelles as a single agent or in combination was investigated against SK-OV-3 human ovarian adenocarcinoma along with its multi-drug resistant (MDR) version SK-OV-3-PCL-resistant (SK-OV-3TR) cells in vitro. Results: Our results indicated that the TF-targeted combination micelles were able to improve the net cytotoxic effect of CUR and PCL to clear synergistic one against the SK-OV-3 cells. In addition, even though the non-targeted combination treatment demonstrated a synergistic effect against the SK-OV-3TR cells, the addition of the TF-targeting moiety significantly increased this cytotoxic effect. While keeping CUR constant at 5 and 10 μM and varying the PCL concentration, the PCL IC50 decreased from ~1.78 to 0.68 μM for the non-targeted formulations to ~0.74 and 0.1 μM for the TF-targeted ones, respectively. Conclusion: Our results indicate that such co-loaded targeted mixed micelles could have significant clinical advantages for the treatment of resistant ovarian cancer and provide a clear rational for further in vivo investigation. © 2014 Springer Science+Business Media New York.

Alroqi F.J.,Room 214 | Chatila T.A.,Harvard University
Current allergy and asthma reports | Year: 2016

Regulatory T (Treg) cells that express the transcription factor forkhead box protein P3 (FOXP3) play an essential role in enforcing immune tolerance to self tissues, regulating host-commensal flora interaction, and facilitating tissue repair. Their deficiency and/or dysfunction trigger unbridled autoimmunity and inflammation. A growing number of monogenic defects have been recognized that adversely impact Treg cell development, differentiation, and/or function, leading to heritable diseases of immune dysregulation and autoimmunity. In this article, we review recent insights into Treg cell biology and function, with particular attention to lessons learned from newly recognized clinical disorders of Treg cell deficiency.

Essex S.,Room 214 | Navarro G.,Room 214 | Sabhachandani P.,Room 214 | Chordia A.,Room 214 | And 4 more authors.
Gene Therapy | Year: 2015

Multidrug resistance (MDR) mediated by P-glycoprotein overexpression in solid tumors is a major factor in the failure of many forms of chemotherapy. Here we evaluated phospholipid-modified, low-molecular-weight polyethylenimine (DOPE-PEI) nanocarriers for intravenous delivery of anti-P-pg siRNA to tumors with the final goal of modulating MDR in breast cancer. First, we studied the biodistribution of DOPE-PEI nanocarriers and the effect of PEG coating in a subcutaneous breast tumor model. Four hours postinjection, PEGylated carriers showed an 8% injected dose (ID) accumulation in solid tumor via the enhanced permeability and retention effect and 22% ID in serum due to a prolonged, PEG-mediated circulation. Second, we established the therapeutic efficacy and safety of DOPE-PEI/siRNA-mediated P-gp downregulation in combination with doxorubicin (Dox) chemotherapy in MCF-7/MDR xenografts. Weekly injection of siRNA nanopreparations and Dox for up to 5 weeks sensitized the tumors to otherwise non-effective doses of Dox and decreased the tumor volume by threefold vs controls. This therapeutic improvement in response to Dox was attributed to the significant, sequence-specific P-gp downregulation in excised tumors mediated by the DOPE-PEI formulations. © 2015 Macmillan Publishers Limited. All rights reserved.

Cross D.M.,Virginia Polytechnic Institute and State University | Canfield R.A.,Virginia Polytechnic Institute and State University | Canfield R.A.,Room 214
Structural and Multidisciplinary Optimization | Year: 2014

Utilizing gradient-based optimization for large scale, multidisciplinary design problems requires accurate and efficient sensitivity or design derivative analysis. In general, numerical sensitivity methods, such as the finite difference method, are easy to implement but can be computationally expensive and inaccurate. In contrast, analytic sensitivity methods, such as the discrete and continuum methods, are highly accurate but can be very difficult, if not infeasible, to implement. A popular compromise is the semi-analytic method, but it too can be highly inaccurate when computing shape design derivatives. Presented here is an alternative method, which is easy to implement and can be as accurate as conventional analytic sensitivity methods. In this paper a general local continuum shape sensitivity method with spatial gradient reconstruction (SGR) is formulated. It is demonstrated that SGR, a numerical technique, can be used to solve the continuous sensitivity equations (CSEs) in a non-intrusive manner. The method is used to compute design derivatives for a variety of applications, including linear static beam bending, linear transient gust analysis of a 2-D beam structure, linear static bending of rectangular plates, and linear static bending of a beam-stiffened plate. Analysis is conducted with Nastran, and both displacement and stress design derivative solutions are presented. For each example the design derivatives are validated with either analytic or finite difference solutions. © 2014, Springer-Verlag Berlin Heidelberg.

PubMed | Room 214 and Michael bakey Va Medical Center
Type: Journal Article | Journal: Military medicine | Year: 2016

Practice guidelines for post-traumatic stress disorder (PTSD) treatment suggest that inpatient care may be warranted when the severity of the clinical presentation is marred with significant concerns about suicidality and psychiatric comorbidity. Yet, limited guidance exists on conducting trauma-focused treatment in acute hospital settings beyond the traditional medical or stabilization model.The purpose of this current article is to describe and evaluate the integration of evidence-based treatments (EBTs) for PTSD implemented in two gender-specific, Veterans Affairs inpatient programs. The theoretical underpinnings of these trauma-focused programs are elucidated in this article, and program delivery is explained. The concurrent versus sequential delivery of multiple EBTs over the course of a 30-day, cohorted admission is explained.Paired sample t tests were conducted to determine the effectiveness of these programs on PTSD and depressive symptom severity, and clinically significant reductions in symptoms were found. The characteristics of 584 Veterans (men = 290 and women = 284) who were voluntarily admitted for intensive, trauma-focused work are presented. Treatment completion among the men was 74.8% and 92.4% among the women. Participants perceptions of treatment acceptability were examined and presented.These preliminary results offer promising evidence for interventions that concurrently provide strategies for increasing coping skills, suicidal disruption, and emotion dysregulation while providing EBTs for PTSD.

PubMed | Room 214
Type: | Journal: The Cochrane database of systematic reviews | Year: 2016

Atherosclerotic peripheral arterial disease (PAD) can lead to disabling ischemia and limb loss. Treatment modalities have included risk factor optimization through life-style modifications and medications, or operative approaches using both open and minimally invasive techniques, such as balloon angioplasty. Drug-eluting balloon (DEB) angioplasty has emerged as a promising alternative to uncoated balloon angioplasty for the treatment of this difficult disease process. By ballooning and coating the inside of atherosclerotic vessels with cytotoxic agents, such as paclitaxel, cellular mechanisms responsible for atherosclerosis and neointimal hyperplasia are inhibited and its devastating complications are prevented or postponed. DEBs are considerably more expensive than uncoated balloons, and their efficacy in improving patient outcomes is unclear.To assess the efficacy of drug-eluting balloons (DEBs) compared with uncoated, nonstenting balloon angioplasty in people with symptomatic lower-limb peripheral arterial disease (PAD).The Cochrane Vascular Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched December 2015) and Cochrane Register of Studies (CRS) (2015, Issue 11). The TSC searched trial databases for details of ongoing and unpublished studies.We included all randomized controlled trials that compared DEBs with uncoated, nonstenting balloon angioplasty for intermittent claudication (IC) or critical limb ischemia (CLI).Two review authors (AK, TA) independently selected the appropriate trials and performed data extraction, assessment of trial quality, and data analysis. The senior review author (DKR) adjudicated any disagreements.Eleven trials that randomized 1838 participants met the study inclusion criteria. Seven of the trials included femoropopliteal arterial lesions, three included tibial arterial lesions, and one included both. The trials were carried out in Europe and in the USA and all used the taxane drug paclitaxel in the DEB arm. Nine of the 11 trials were industry-sponsored. Four companies manufactured the DEB devices (Bard, Bavaria Medizin, Biotronik, and Medtronic). The trials examined both anatomic and clinical endpoints. There was heterogeneity in the frequency of stent deployment and the type and duration of antiplatelet therapy between trials. Using GRADE assessment criteria, the quality of the evidence presented was moderate for the outcomes of target lesion revascularization and change in Rutherford category, and high for amputation, primary vessel patency, binary restenosis, death, and change in ankle-brachial index (ABI). Most participants were followed up for 12 months, but one trial reported outcomes at five years.There were better outcomes for DEBs for up to two years in primary vessel patency (odds ratio (OR) 1.47, 95% confidence interval (CI) 0.22 to 9.57 at six months; OR 1.92, 95% CI 1.45 to 2.56 at 12 months; OR 3.51, 95% CI 2.26 to 5.46 at two years) and at six months and two years for late lumen loss (mean difference (MD) -0.64 mm, 95% CI -1.00 to -0.28 at six months; MD -0.80 mm, 95% CI -1.44 to -0.16 at two years). DEB were also superior to uncoated balloon angioplasty for up to five years in target lesion revascularization (OR 0.28, 95% CI 0.17 to 0.47 at six months; OR 0.40, 95% CI 0.31 to 0.51 at 12 months; OR 0.28, 95% CI 0.18 to 0.44 at two years; OR 0.21, 95% CI 0.09 to 0.51 at five years) and binary restenosis rate (OR 0.44, 95% CI 0.29 to 0.67 at six months; OR 0.38, 95% CI 0.15 to 0.98 at 12 months; OR 0.26, 95% CI 0.10 to 0.66 at two years; OR 0.12, 95% CI 0.05 to 0.30 at five years). There was no significant difference between DEB and uncoated angioplasty in amputation, death, change in ABI, change in Rutherford category and quality of life (QoL) scores, or functional walking ability, although none of the trials were powered to detect a significant difference in these clinical endpoints. We carried out two subgroup analyses to examine outcomes in femoropopliteal and tibial interventions as well as in people with CLI (4 or greater Rutherford class), and showed no advantage for DEBs in tibial vessels at six and 12 months compared with uncoated balloon angioplasty. There was also no advantage for DEBs in CLI compared with uncoated balloon angioplasty at 12 months.Based on a meta-analysis of 11 trials with 1838 participants, there is evidence of an advantage for DEBs compared with uncoated balloon angioplasty in several anatomic endpoints such as primary vessel patency (high-quality evidence), binary restenosis rate (moderate-quality evidence), and target lesion revascularization (low-quality evidence) for up to 12 months. Conversely, there is no evidence of an advantage for DEBs in clinical endpoints such as amputation, death, or change in ABI, or change in Rutherford category during 12 months follow-up. Well-designed randomized trials with long-term follow-up are needed to compare DEBs with uncoated balloon angioplasties adequately for both anatomic and clinical study endpoints before the widespread use of this expensive technology can be justified.

News Article | November 17, 2016

Boulder-based Room 214, a digital and social media marketing agency, announced that it was named one of the 2016 Best Places to Work in the country by Outside Magazine. Some of the attributes Outside Magazine highlighted are Room 214’s creative culture and an emphasis on a work-life balance. Room 214 offers unlimited paid days off, a dog-friendly office and weekly in-house activities ranging from happy hours to fun runs. It also offers profit sharing and 401(k) matching. Staff members recently improved on an employee incentive program that includes progressive recruitment bonuses and paid, in-state vacations after employees hit their 5-year anniversary with the agency. “This kind of recognition is on everyone in the agency,” said Room 214 Co-founder Jason Cormier. “When people can lead with humility, are really interested in doing their best work, and are acting out of love instead of fear -- well, that’s going to be a great place to work.” Room 214 values giving back, with its time, talent and treasure. In addition to its pro-bono work on behalf of nonprofits, the company hosts regular fundraisers, food drives and volunteer events involving the entire company. “This year’s list of Best Places to Work highlights employers who go above and beyond for their staff,” said Outside Online Editor Scott Rosenfield. “Included are organizations that emphasize a healthy work-life balance and promote, encourage and reward employees to live active and healthier lives.” The agency practices a unique model of open book management, offering complete financial transparency -- and a means for everyone (from intern to partner) to contribute to the company’s vision and success. In addition to Outside Magazine’s published list, Room 214 also just announced its inclusion as one of the Top 250 Private Companies in Colorado by ColoradoBiz magazine. About Room 214 Room 214 is a digital marketing and social media agency dedicated to helping brands connect with the people who matter most. Recognized as one of the Best Places to Work in America by Outside Magazine, a Top 250 Private Company by ColoradoBiz, and one of the fastest growing companies by Inc. Magazine, Room 214 succeeds by molding thoughtful insights into intriguing content -- and developing strategic marketing initiatives that integrate all facets of digital and social marketing for B2B and B2C companies. With headquarters in Boulder, Colo. services include: brand and messaging strategy; digital and social media campaign execution; consumer research and analytics; online advertising and search engine optimization; content creation with in-house copy, photography and video production capabilities. A sample of Room 214’s clients include: Sanrio (Hello Kitty), Panasonic, Boulder Brands, Crock-Pot, Mr. Coffee, Adobe, Verizon, Twitter, Western Union, Haribo and Whitewave Foods. Make the connection and join Room 214 in conversation at:, @Room_214,, and info(at)room214(dot)com.

Loading Room 214 collaborators
Loading Room 214 collaborators